- Previous Close
670.00 - Open
678.00 - Bid 678.00 x --
- Ask 675.00 x --
- Day's Range
666.00 - 684.00 - 52 Week Range
281.00 - 734.00 - Volume
1,132,684 - Avg. Volume
4,283,853 - Market Cap (intraday)
223.072B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
164.79 - EPS (TTM)
4.09 - Earnings Date Nov 8, 2024 - Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
681.00
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
www.pharmaessentia.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6446.TW
View More
Performance Overview: 6446.TW
Trailing total returns as of 9/5/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6446.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6446.TW
View MoreValuation Measures
Market Cap
221.75B
Enterprise Value
202.74B
Trailing P/E
164.22
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
32.71
Price/Book (mrq)
8.76
Enterprise Value/Revenue
29.85
Enterprise Value/EBITDA
128.98
Financial Highlights
Profitability and Income Statement
Profit Margin
19.16%
Return on Assets (ttm)
-0.71%
Return on Equity (ttm)
5.24%
Revenue (ttm)
6.91B
Net Income Avi to Common (ttm)
1.32B
Diluted EPS (ttm)
4.09
Balance Sheet and Cash Flow
Total Cash (mrq)
20.06B
Total Debt/Equity (mrq)
4.25%
Levered Free Cash Flow (ttm)
-1.12B
Research Analysis: 6446.TW
View MoreCompany Insights: 6446.TW
6446.TW does not have Company Insights